CNR1 and scleroderma: Indeed, another PPARγ and CB2 co-activator (and CB1 antagonist), namely “VCE-004.3” (a semi-synthetic CBD quinol derivative) was also found to alleviate bleomycin-induced scleroderma as well as exerting potent anti-fibrotic effects via activating PPARγ and CB2 [242].